Novelix Pharmaceuticals Ltd
₹ 58.2
-4.96%
12 Dec
- close price
About
Incorporated in 1994, Novelix Pharmaceuticals Ltd trades in Pharmaceuticals and related products , shares, and securities[1]
Key Points
- Market Cap ₹ 108 Cr.
- Current Price ₹ 58.2
- High / Low ₹ 70.2 / 24.2
- Stock P/E
- Book Value ₹ 8.89
- Dividend Yield 0.00 %
- ROCE -25.7 %
- ROE -25.0 %
- Face Value ₹ 10.0
Pros
- Promoter holding has increased by 2.07% over last quarter.
- Company's working capital requirements have reduced from 163 days to 87.7 days
Cons
- Stock is trading at 6.55 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -0.62% over past five years.
- Company has a low return on equity of -21.8% over last 3 years.
- Promoter holding has decreased over last 3 years: -12.1%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.95 | 5.74 | 6.35 | 5.72 | 9.19 | 10.51 | 10.73 | 10.85 | 9.59 | 8.91 | 4.40 | |
| 5.13 | 4.86 | 5.66 | 5.24 | 9.06 | 10.47 | 10.62 | 10.75 | 13.06 | 11.10 | 7.34 | |
| Operating Profit | 0.82 | 0.88 | 0.69 | 0.48 | 0.13 | 0.04 | 0.11 | 0.10 | -3.47 | -2.19 | -2.94 |
| OPM % | 13.78% | 15.33% | 10.87% | 8.39% | 1.41% | 0.38% | 1.03% | 0.92% | -36.18% | -24.58% | -66.82% |
| 0.00 | 0.02 | 0.00 | 0.11 | 0.30 | 0.15 | 0.11 | 0.00 | 0.00 | 0.32 | 0.33 | |
| Interest | 0.01 | 0.01 | 0.01 | 0.00 | 0.05 | 0.16 | 0.13 | 0.12 | 0.07 | 0.06 | 0.00 |
| Depreciation | 0.27 | 0.29 | 0.41 | 0.35 | 0.19 | 0.24 | 0.21 | 0.19 | 0.21 | 0.10 | 0.05 |
| Profit before tax | 0.54 | 0.60 | 0.27 | 0.24 | 0.19 | -0.21 | -0.12 | -0.21 | -3.75 | -2.03 | -2.66 |
| Tax % | 31.48% | 31.67% | 48.15% | 45.83% | 84.21% | 66.67% | 25.00% | 23.81% | 0.27% | -0.49% | |
| 0.38 | 0.42 | 0.15 | 0.13 | 0.03 | -0.35 | -0.15 | -0.26 | -3.76 | -2.03 | -2.54 | |
| EPS in Rs | 0.47 | 0.52 | 0.11 | 0.12 | -0.01 | -0.43 | -0.30 | -0.35 | -4.62 | -2.22 | -2.69 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -6% |
| TTM: | -62% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 56% |
| 3 Years: | 89% |
| 1 Year: | 153% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -13% |
| 3 Years: | -22% |
| Last Year: | -25% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 |
| Reserves | 2.93 | 3.35 | 3.33 | 3.45 | 3.44 | 3.07 | 2.82 | 2.50 | -1.24 | -0.70 | -0.90 |
| 0.07 | 0.04 | 0.00 | 0.00 | 0.99 | 0.98 | 0.93 | 0.77 | 0.00 | 0.16 | 1.02 | |
| 0.44 | 0.69 | 1.08 | 1.19 | 1.22 | 1.43 | 1.49 | 2.35 | 2.72 | 1.18 | 0.23 | |
| Total Liabilities | 11.54 | 12.18 | 12.51 | 12.74 | 13.75 | 13.58 | 13.34 | 13.72 | 9.58 | 8.74 | 8.45 |
| 1.22 | 1.17 | 0.75 | 0.70 | 2.10 | 2.17 | 1.92 | 1.83 | 1.65 | 2.20 | 2.17 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.02 | 0.05 | 1.14 | 1.69 | 0.33 | 0.63 | 0.49 | 0.30 | 0.39 | 0.42 | 0.42 |
| 10.30 | 10.96 | 10.62 | 10.09 | 11.32 | 10.78 | 10.93 | 11.59 | 7.54 | 6.12 | 5.86 | |
| Total Assets | 11.54 | 12.18 | 12.51 | 12.74 | 13.75 | 13.58 | 13.34 | 13.72 | 9.58 | 8.74 | 8.45 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.45 | 0.05 | 0.30 | 2.05 | -1.82 | 0.37 | -0.53 | 0.63 | 1.59 | 1.59 | |
| 1.06 | 0.73 | -1.40 | -1.06 | 0.21 | -0.64 | 0.43 | 0.45 | 0.14 | -0.76 | |
| 2.40 | 0.17 | -0.01 | 0.22 | 0.77 | 0.02 | -0.05 | -0.16 | -0.77 | 0.00 | |
| Net Cash Flow | 0.01 | 0.95 | -1.11 | 1.22 | -0.84 | -0.24 | -0.15 | 0.92 | 0.96 | 0.83 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 50.30 | 54.05 | 38.51 | 33.82 | 48.85 | 75.36 | 111.92 | 44.07 | 52.52 | 50.39 |
| Inventory Days | 26.47 | 27.55 | 35.78 | 40.85 | 48.28 | 42.65 | 38.29 | 43.94 | 48.42 | 43.87 |
| Days Payable | 1.60 | 4.30 | 38.17 | 32.86 | 27.52 | 39.67 | 39.26 | 79.66 | 111.95 | 38.61 |
| Cash Conversion Cycle | 75.17 | 77.29 | 36.13 | 41.81 | 69.61 | 78.34 | 110.95 | 8.34 | -11.00 | 55.65 |
| Working Capital Days | 568.05 | 572.30 | 539.17 | 492.62 | 382.08 | 321.59 | 324.18 | 284.60 | 116.85 | 87.67 |
| ROCE % | 5.35% | 2.39% | 2.19% | 0.88% | -0.08% | -0.80% | -0.74% | -38.23% | -25.67% |
Documents
Announcements
-
Shareholders Meeting- EGM On January 09, 2026.
1d - EGM on 09-Jan-2026 via VC; cut-off 02-Jan-2026; remote e-voting 06–08 Jan 2026.
-
Announcement under Regulation 30 (LODR)-Preferential Issue
1d - Preferential allotment of 2,500,000 shares at Rs60 (Rs15 crore) approved Dec 11, 2025 to promoters/non-promoters.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday, 11Th December, 2025.
1d - Preferential allotment of 2,500,000 shares at Rs60 (aggregate Rs15 crore); EGM on 9 January 2026.
- Closure of Trading Window 8 Dec
-
Board Meeting Intimation for Prior Intimation Of Board Meeting Scheduled To Be Held On Thursday, 11Th December, 2025
8 Dec - Board meeting 11 Dec 2025 to consider preferential allotment; EGM notice and trading-window closure.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2][3]
NPL is a recent entrant in the life sciences research and pharmaceutical intermediates business. In FY24, the company altered its objectives to expand into the pharmaceutical bulk drug segment and healthcare research, analytics, and technology. Currently, it is engaged in pharmaceutical research and the production and trading of bulk drugs (Active Pharmaceutical Ingredients) as well as key starting materials and intermediates.